{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:52:50Z","timestamp":1785293570588,"version":"3.55.0"},"reference-count":81,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIH\/NIAID","doi-asserted-by":"publisher","award":["AI125626"],"award-info":[{"award-number":["AI125626"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIH\/NIAID","doi-asserted-by":"publisher","award":["AI128556"],"award-info":[{"award-number":["AI128556"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Texas Biomedical Research Institute Forum Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Several mammarenaviruses (MaAv), chiefly Lassa virus (LASV) in Western Africa and Junin virus (JUNV) in the Argentinean Pampas, cause severe disease in humans and pose important public health problems in their endemic regions. In addition, the globally distributed MaAv lymphocytic choriomeningitis virus (LCMV) is an underrecognized human pathogen of clinical significance, especially in congenital infections, and LCMV poses a serious risk for immunocompromised individuals. There are no FDA-approved MaAv vaccines or antivirals, and current anti-MaAv therapy is limited to an off-label use of ribavirin, whose efficacy remains controversial. This highlights an urgent unmet need for developing antivirals against human pathogenic MaAv. Halofuginone (HF), a derivative of the natural alkaloid febrifugine, has been shown to exhibit antiviral activity against several RNA viruses. Here, we present evidence that HF exhibits potent dose-dependent antiviral activity against LCMV, and against the hemorrhagic fever causing MaAv LASV and JUNV. HF binds to the bifunctional enzyme glutamyl-prolyl-tRNA synthetase 1 (EPRS1) and specifically inhibits its prolyl-tRNA synthetase (PRS) activity, resulting in translation inhibition via the amino acid starvation (AAS) response with preferential impact on proline-rich proteins. HF anti-LCMV activity was prevented by the addition of exogenous proline supporting that inhibition of PRS activity plays a critical role in the anti-MaAv activity of HF. We found that HF did not affect LCMV cell entry, modestly (twofold) reduced the activity of the virus ribonucleoprotein (vRNP), but strongly inhibited (&gt;90%) Z budding activity, a process involving the Z proline-rich late domain motifs.<\/jats:p>","DOI":"10.3390\/v18020202","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T09:02:01Z","timestamp":1770195721000},"page":"202","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prolyl tRNA Synthetase Is Required for Mammarenavirus Multiplication"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0174-8454","authenticated-orcid":false,"given":"Haydar","family":"Witwit","sequence":"first","affiliation":[{"name":"Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ibanez","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2844-0107","authenticated-orcid":false,"given":"Ruifeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9654-6926","authenticated-orcid":false,"given":"Nathaniel","family":"Jackson","sequence":"additional","affiliation":[{"name":"Texas Biomedical Research Institute, San Antonio, TX 78227, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Escobedo","sequence":"additional","affiliation":[{"name":"Texas Biomedical Research Institute, San Antonio, TX 78227, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8048-410X","authenticated-orcid":false,"given":"Beatrice","family":"Cubitt","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9142-4483","authenticated-orcid":false,"given":"Roaa","family":"Khafaji","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Sattler","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7084-0804","authenticated-orcid":false,"given":"Luis","family":"Martinez-Sobrido","sequence":"additional","affiliation":[{"name":"Texas Biomedical Research Institute, San Antonio, TX 78227, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8171-8115","authenticated-orcid":false,"given":"Juan","family":"de la Torre","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Basinski, A.J., Fichet-Calvet, E., Sjodin, A.R., Varrelman, T.J., Remien, C.H., Layman, N.C., Bird, B.H., Wolking, D.J., Monagin, C., and Ghersi, B.M. (2021). Bridging the Gap: Using Reservoir Ecology and Human Serosurveys to Estimate Lassa Virus Spillover in West Africa. PLoS Comput. Biol., 17.","DOI":"10.1371\/journal.pcbi.1008811"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Fichet-Calvet, E., and Rogers, D.J. (2009). Risk Maps of Lassa Fever in West Africa. PLoS Neglected Trop. Dis., 3.","DOI":"10.1371\/journal.pntd.0000388"},{"key":"ref_3","first-page":"165","article-title":"Lassa Fever Natural History and Clinical Management","volume":"440","author":"Grant","year":"2023","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_4","unstructured":"Knipe, D.M., Howley, P., and Whelan, S. (2020). Emerging Viruses: Arenaviridae. Fields Virology, LWW."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1863-2378.2012.01469.x","article-title":"Lassa Fever in West Africa: Evidence for an Expanded Region of Endemicity","volume":"59","author":"Sogoba","year":"2012","journal-title":"Zoonoses Public Health"},{"key":"ref_6","first-page":"865","article-title":"Emerging Infectious Diseases and Risk to the Traveler","volume":"83","author":"Freedman","year":"1999","journal-title":"Med. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1086\/322620","article-title":"Viral Hemorrhagic Fever Hazards for Travelers in Africa","volume":"33","author":"Ericsson","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e2002324118","DOI":"10.1073\/pnas.2002324118","article-title":"Ranking the Risk of Animal-to-Human Spillover for Newly Discovered Viruses","volume":"118","author":"Grange","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3390\/v4102317","article-title":"Jun\u00edn Virus Pathogenesis and Virus Replication","volume":"4","author":"Grant","year":"2012","journal-title":"Viruses"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lendino, A., Castellanos, A.A., Pigott, D.M., and Han, B.A. (2024). A Review of Emerging Health Threats from Zoonotic New World Mammarenaviruses. BMC Microbiol., 24.","DOI":"10.1186\/s12866-024-03257-w"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1001\/jama.287.18.2391","article-title":"Hemorrhagic Fever Viruses as Biological Weapons: Medical and Public Health Management","volume":"287","author":"Borio","year":"2002","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.yapd.2009.08.007","article-title":"Lymphocytic Choriomeningitis Virus: A Prenatal and Postnatal Threat","volume":"56","author":"Bonthius","year":"2009","journal-title":"Adv. Pediatr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMoa073785","article-title":"A New Arenavirus in a Cluster of Fatal Transplant-Associated Diseases","volume":"358","author":"Palacios","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/pd.6192","article-title":"Congenital Lymphocytic Choriomeningitis Virus: A Review","volume":"42","author":"Pencole","year":"2022","journal-title":"Prenat. Diagn"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4149\/av_2013_02_160","article-title":"Lymphocytic Choriomeningitis Virus: Invisible but Not Innocent","volume":"57","year":"2013","journal-title":"Acta Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2542250","DOI":"10.1080\/22221751.2025.2542250","article-title":"Discovery of a Novel Lymphocytic Choriomeningitis Virus Strain Associated with Severe Human Disease in Immunocompetent Patient, New Mexico","volume":"14","author":"Gass","year":"2025","journal-title":"Emerg. Microbes Infect."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Salam, A.P., Cheng, V., Edwards, T., Olliaro, P., Sterne, J., and Horby, P. (2021). Time to Reconsider the Role of Ribavirin in Lassa Fever. PLoS Neglected Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009522"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coviro.2019.07.003","article-title":"Antibody Therapy for Lassa Fever","volume":"37","author":"Cross","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Gowen, B.B., Juelich, T.L., Sefing, E.J., Brasel, T., Smith, J.K., Zhang, L., Tigabu, B., Hill, T.E., Yun, T., and Pietzsch, C. (2013). Favipiravir (T-705) Inhibits Jun\u00edn Virus Infection and Reduces Mortality in a Guinea Pig Model of Argentine Hemorrhagic Fever. PLoS Neglected Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002614"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/AAC.01219-10","article-title":"T-705 (Favipiravir) Inhibition of Arenavirus Replication in Cell Culture","volume":"55","author":"Mendenhall","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3201\/eid2409.180233","article-title":"Use of Favipiravir to Treat Lassa Virus Infection in Macaques","volume":"24","author":"Rosenke","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"14775","DOI":"10.1038\/srep14775","article-title":"The Broad-Spectrum Antiviral Favipiravir Protects Guinea Pigs from Lethal Lassa Virus Infection Post-Disease Onset","volume":"5","author":"Safronetz","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1089\/dna.2022.0312","article-title":"4\u2032-Fluorouridine Is a Broad-Spectrum Orally Available First-Line Antiviral That May Improve Pandemic Preparedness","volume":"41","author":"Lieber","year":"2022","journal-title":"DNA Cell Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"eado7034","DOI":"10.1126\/scitranslmed.ado7034","article-title":"Delayed Low-Dose Oral Administration of 4\u2032-Fluorouridine Inhibits Pathogenic Arenaviruses in Animal Models of Lethal Disease","volume":"16","author":"Welch","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"19911","DOI":"10.1038\/s41598-022-23760-2","article-title":"Lassa Antiviral LHF-535 Protects Guinea Pigs from Lethal Challenge","volume":"12","author":"Cashman","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"105125","DOI":"10.1016\/j.antiviral.2021.105125","article-title":"Potent Inhibition of Arenavirus Infection by a Novel Fusion Inhibitor","volume":"193","author":"Gowen","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102858","DOI":"10.1016\/j.jiph.2025.102858","article-title":"Electrocardiographic Alterations in Patients Treated for Acute Lassa Fever: Description of Results from a Phase II Clinical Trial in Nigeria","volume":"18","author":"Erameh","year":"2025","journal-title":"J. Infect. Public Health"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.cell.2015.07.020","article-title":"Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus","volume":"162","author":"Andersen","year":"2015","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s13238-018-0604-x","article-title":"Structure-Activity Relationship Optimization for Lassa Virus Fusion Inhibitors Targeting the Transmembrane Domain of GP2","volume":"10","author":"Zhang","year":"2019","journal-title":"Protein Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.ejca.2005.12.027","article-title":"Phase I and Pharmacokinetic Study of Halofuginone, an Oral Quinazolinone Derivative in Patients with Advanced Solid Tumours","volume":"42","author":"Dumez","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/QAI.0b013e3181fc0141","article-title":"Phase II AIDS Malignancy Consortium Trial of Topical Halofuginone in AIDS-Related Kaposi Sarcoma","volume":"56","author":"Koon","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1083-8791(03)00151-4","article-title":"Halofuginone to Treat Fibrosis in Chronic Graft-versus-Host Disease and Scleroderma","volume":"9","author":"Pines","year":"2003","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105798","DOI":"10.1016\/j.antiviral.2024.105798","article-title":"Assessment of the Broad-Spectrum Host Targeting Antiviral Efficacy of Halofuginone Hydrobromide in Human Airway, Intestinal and Brain Organotypic Models","volume":"222","author":"Moreni","year":"2024","journal-title":"Antivir. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.antiviral.2018.11.017","article-title":"A Potent Prolyl tRNA Synthetase Inhibitor Antagonizes Chikungunya and Dengue Viruses","volume":"161","author":"Hwang","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1161\/CIRCRESAHA.119.315999","article-title":"Glutamyl-Prolyl-tRNA Synthetase Regulates Proline-Rich Pro-Fibrotic Protein Synthesis During Cardiac Fibrosis","volume":"127","author":"Wu","year":"2020","journal-title":"Circ. Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Iwasaki, M., Minder, P., Ca\u00ec, Y., Kuhn, J.H., Yates, J.R., Torbett, B.E., and de la Torre, J.C. (2018). Interactome Analysis of the Lymphocytic Choriomeningitis Virus Nucleoprotein in Infected Cells Reveals ATPase Na+\/K+ Transporting Subunit Alpha 1 and Prohibitin as Host-Cell Factors Involved in the Life Cycle of Mammarenaviruses. PLoS Pathog., 14, Correction in PLoS Pathog. 2018, 16, e1008289. https:\/\/doi.org\/10.1371\/journal.ppat.1008289.","DOI":"10.1371\/journal.ppat.1008289"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1128\/JVI.02102-10","article-title":"Rescue from Cloned cDNAs and In Vivo Characterization of Recombinant Pathogenic Romero and Live-Attenuated Candid #1 Strains of Junin Virus, the Causative Agent of Argentine Hemorrhagic Fever Disease","volume":"85","author":"Emonet","year":"2011","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e0188323","DOI":"10.1128\/jvi.01883-23","article-title":"Activation of Protein Kinase Receptor (PKR) Plays a pro-Viral Role in Mammarenavirus-Infected Cells","volume":"98","author":"Witwit","year":"2024","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Witwit, H., Betancourt, C.A., Cubitt, B., Khafaji, R., Kowalski, H., Jackson, N., Ye, C., Martinez-Sobrido, L., and de la Torre, J.C. (2024). Cellular N-Myristoyl Transferases Are Required for Mammarenavirus Multiplication. Viruses, 16.","DOI":"10.1101\/2024.08.01.606235"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0166-0934(91)90018-U","article-title":"Quantification of Lymphocytic Choriomeningitis Virus with an Immunological Focus Assay in 24- or 96-Well Plates","volume":"33","author":"Battegay","year":"1991","journal-title":"J. Virol. Methods"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1128\/JVI.77.2.1184-1194.2003","article-title":"Characterization of the Genomic Promoter of the Prototypic Arenavirus Lymphocytic Choriomeningitis Virus","volume":"77","author":"Perez","year":"2003","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.virol.2008.04.046","article-title":"Lymphocytic Choriomeningitis Virus Uses a Novel Endocytic Pathway for Infectious Entry via Late Endosomes","volume":"378","author":"Quirin","year":"2008","journal-title":"Virology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/viro.1994.1001","article-title":"Mechanism of Lymphocytic Choriomeningitis Virus Entry into Cells","volume":"198","author":"Borrow","year":"1994","journal-title":"Virology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1073\/pnas.77.6.3273","article-title":"pH-Dependent Fusion between the Semliki Forest Virus Membrane and Liposomes","volume":"77","author":"White","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"11443","DOI":"10.1128\/JVI.78.20.11443-11448.2004","article-title":"Myristoylation of the RING Finger Z Protein Is Essential for Arenavirus Budding","volume":"78","author":"Perez","year":"2004","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Witwit, H., and de la Torre, J.C. (2025). Mammarenavirus Z Protein Myristoylation and Oligomerization Are Not Required for Its Dose-Dependent Inhibitory Effect on vRNP Activity. BioChem, 5.","DOI":"10.1101\/2025.04.17.649453"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.virol.2008.09.008","article-title":"A Cell-Based Luciferase Assay Amenable to High-Throughput Screening of Inhibitors of Arenavirus Budding","volume":"382","author":"Capul","year":"2008","journal-title":"Virology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.0502165102","article-title":"Structure and ESCRT-III Protein Interactions of the MIT Domain of Human VPS4A","volume":"102","author":"Scott","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0092-8674(01)00506-2","article-title":"Tsg101 and the Vacuolar Protein Sorting Pathway Are Essential for HIV-1 Budding","volume":"107","author":"Garrus","year":"2001","journal-title":"Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nm1201-1313","article-title":"HIV-1 and Ebola Virus Encode Small Peptide Motifs That Recruit Tsg101 to Sites of Particle Assembly to Facilitate Egress","volume":"7","author":"Zang","year":"2001","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0092-8674(03)00653-6","article-title":"AIP1\/ALIX Is a Binding Partner for HIV-1 P6 and EIAV P9 Functioning in Virus Budding","volume":"114","author":"Strack","year":"2003","journal-title":"Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"11330","DOI":"10.1128\/JVI.00763-09","article-title":"Identification of Amino Acid Residues Critical for the Anti-Interferon Activity of the Nucleoprotein of the Prototypic Arenavirus Lymphocytic Choriomeningitis Virus","volume":"83","author":"Emonet","year":"2009","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e202405175","DOI":"10.1083\/jcb.202405175","article-title":"Integrated Stress Response Activator Halofuginone Protects Mice from Diabetes-like Phenotypes","volume":"223","author":"Rai","year":"2024","journal-title":"J. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e109985","DOI":"10.15252\/embj.2021109985","article-title":"Cellular Responses to Halofuginone Reveal a Vulnerability of the GCN2 Branch of the Integrated Stress Response","volume":"41","author":"Pitera","year":"2022","journal-title":"EMBO J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"103667","DOI":"10.1016\/j.ibmb.2021.103667","article-title":"Halofuginone Triggers a Transcriptional Program Centered on Ribosome Biogenesis and Function in Honey Bees","volume":"139","author":"Flores","year":"2021","journal-title":"Insect Biochem. Mol. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Kamberov, Y.G., Kim, J., Mazitschek, R., Kuo, W.P., and Whitman, M. (2011). Microarray Profiling Reveals the Integrated Stress Response Is Activated by Halofuginone in Mammary Epithelial Cells. BMC Res. Notes, 4.","DOI":"10.1186\/1756-0500-4-381"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"104173","DOI":"10.1016\/j.xpro.2025.104173","article-title":"Protocol for Halofuginone-Mediated Metabolic Reprogramming of Murine T Cells via Activation of the GCN2 Pathway","volume":"6","author":"Kates","year":"2025","journal-title":"STAR Protoc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.V116.21.773.773","article-title":"Halofuginone Induces Post-Transcriptional Down-Regulation of Cyclin D1, Cell Cycle Arrest and Apoptosis In Mantle Cell Lymphoma Cells through Activation of Integrated Stress Response Pathways","volume":"116","author":"Santos","year":"2010","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0304-4017(97)00203-3","article-title":"Comparative Efficacy of Anticoccidials under the Conditions of Commercial Broiler Production and in Battery Trials","volume":"76","author":"Daugschies","year":"1998","journal-title":"Vet. Parasitol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00436-012-2889-7","article-title":"Anticoccidial Effect of Halofuginone Hydrobromide against Eimeria Tenella with Associated Histology","volume":"111","author":"Zhang","year":"2012","journal-title":"Parasitol. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.prevetmed.2010.06.017","article-title":"Control of Cryptosporidiosis in Neonatal Calves: Use of Halofuginone Lactate in Two Different Calf Rearing Systems","volume":"96","author":"Speybroeck","year":"2010","journal-title":"Prev. Vet. Med."},{"key":"ref_62","first-page":"11","article-title":"Influence of Phased Inclusion of Halofuginone on Broiler Skin Tensile Strength and Growth Performance","volume":"63","author":"Crosley","year":"1992","journal-title":"J. S Afr. Vet. Assoc."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1365-2141.2012.09120.x","article-title":"Halofuginone Inhibits Multiple Myeloma Growth in Vitro and in Vivo and Enhances Cytotoxicity of Conventional and Novel Agents","volume":"157","author":"Leiba","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3168\/jds.S0022-0302(05)72854-X","article-title":"Effect of Halofuginone Lactate on the Occurrence of Cryptosporidium Parvum and Growth of Neonatal Dairy Calves","volume":"88","author":"Jarvie","year":"2005","journal-title":"J. Dairy Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2885.2007.00900.x","article-title":"Effect of Halofuginone Lactate on Treatment and Prevention of Lamb Cryptosporidiosis: An Extensive Field Trial","volume":"30","author":"Giadinis","year":"2007","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/vr.148.4.108","article-title":"Efficacy of Halofuginone Lactate in the Prevention of Cryptosporidiosis in Suckling Calves","volume":"148","author":"Lefay","year":"2001","journal-title":"Vet. Rec."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vetpar.2013.04.029","article-title":"Utility of Halofuginone Lactate for the Prevention of Natural Cryptosporidiosis of Calves, in the Presence of Co-Infection with Rotavirus and Salmonella Typhimurium","volume":"197","author":"Almawly","year":"2013","journal-title":"Vet. Parasitol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s002800100367","article-title":"Pharmacokinetics and Tissue Distribution of Halofuginone (NSC 713205) in CD2F1 Mice and Fischer 344 Rats","volume":"48","author":"Stecklair","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.bbrc.2016.03.118","article-title":"Halofuginone Alleviates Acute Viral Myocarditis in Suckling BALB\/c Mice by Inhibiting TGF-\u03921","volume":"473","author":"Sun","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.2147\/DDDT.S149623","article-title":"Halofuginone Ameliorates Inflammation in Severe Acute Hepatitis B Virus (HBV)-Infected SD Rats through AMPK Activation","volume":"11","author":"Zhan","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e00168-19","DOI":"10.1128\/CMR.00168-19","article-title":"Host-Directed Antiviral Therapy","volume":"33","author":"Kumar","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S1473-3099(16)00078-5","article-title":"Host-Directed Therapies for Infectious Diseases: Current Status, Recent Progress, and Future Prospects","volume":"16","author":"Zumla","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_73","first-page":"51","article-title":"Viruses as Quasispecies: Biological Implications","volume":"299","author":"Domingo","year":"2006","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"41660","DOI":"10.1038\/srep41660","article-title":"Baseline Quasispecies Selection and Novel Mutations Contribute to Emerging Resistance-Associated Substitutions in Hepatitis C Virus after Direct-Acting Antiviral Treatment","volume":"7","author":"Kai","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"106258","DOI":"10.1016\/j.antiviral.2025.106258","article-title":"N-Myristoyltransferase Inhibitors as Candidate Broad-Spectrum Antivirals to Treat Viral Infections Promoted by Immunosuppression Associated with JAK Inhibitors Therapy","volume":"242","author":"Witwit","year":"2025","journal-title":"Antivir. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug Repurposing: Progress, Challenges and Recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-019-0026-3","article-title":"Aminoacyl-tRNA Synthetases as Therapeutic Targets","volume":"18","author":"Kwon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e16940","DOI":"10.15252\/emmm.202216940","article-title":"Control of Fibrosis with Enhanced Safety via Asymmetric Inhibition of prolyl-tRNA Synthetase 1","volume":"15","author":"Yoon","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"ref_79","unstructured":"Daewoong Pharmaceutical Co, and Ltd (2025, October 13). A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DWN12088 in Patients with Idiopathic Pulmonary Fibrosis, Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1107\/S0907444913020556","article-title":"Conformational Changes in Human Prolyl-tRNA Synthetase upon Binding of the Substrates Proline and ATP and the Inhibitor Halofuginone","volume":"69","author":"Son","year":"2013","journal-title":"Acta Cryst. D"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate Structure Prediction of Biomolecular Interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/2\/202\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:41:39Z","timestamp":1776325299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/2\/202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":81,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["v18020202"],"URL":"https:\/\/doi.org\/10.3390\/v18020202","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]}}}